

# Ralzapastotug Biosimilar - Research Grade

**Product Code:** ICH5803

**More Information**

**Species Reactivity:** Human

**Target:** TIGIT $\frac{1}{2}$

**Concentration:** 5mg/ml

**Isotype:** IgG1 - kappa

**Host:** CHO Cells

**product name H2:** Ralzapastotug Biosimilar - Research Grade

**Sequence:** <https://www.imgt.org/mAb-DB/>

**Buffer:** ICH3002

**UniProt:** Q495A1

**Shipping Conditions:** Blue ice

**background:** TIGIT is an inhibitory checkpoint receptor on T and NK cells and a prominent immuno-oncology target. Modeled on ralzapastotug, this unconjugated, non-therapeutic human IgG1 kappa antibody is expressed in CHO cells against human TIGIT. Released for research use only, it is purified to low endotoxin for in vivo suitability and produced in scalable milligram (mg) to gram (g) quantities for high-throughput, heavy-usage laboratories. It supports checkpoint-blockade functional assays, NK- and T-cell activity studies, ADCC investigations, and preclinical tumor-immunity models. Uniform quality across lots underpins confident comparisons in long-running projects.

**Purification Method:** This monoclonal antibody was purified using Protein A

**Formulation:** Sterile, preservative-free, solution in PBS. BSA and Azide free.



**Purity:** >90% by SDS-PAGE

**Endotoxin:**  $\leq 1.0$  EU/mg as determined by the LAL method

**Storage:** This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

**Applications:** Functional Assays

**Application Notes:** This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

**Use:** Products are for research use only. Not for use in diagnostic or therapeutic procedures.

**Delivery Time:** 3-4 weeks